Differential expression of LYZ across pan-cancer and its prognostic value and immune microenvironment regulatory mechanisms in glioma
- 1Department of Radiotherapy, The Second Hospital of Hebei Medical University
- 2Department of Oncology, Handan Central Hospital
Abstract
Purpose To investigate the expression patterns of the immune factor Lysozyme (LYZ) across pan-cancer, with a focus on elucidating its prognostic value, molecular mechanisms, and association with the immune microenvironment in glioma, aiming to identify novel therapeutic targets for precision oncology. Methods Utilizing The Cancer Genome Atlas (TCGA) pan-cancer datasets, we analyzed differential expression of LYZ between tumor and normal tissues, correlated clinical features, tumor stemness, and prognosis. Univariate/multivariate Cox regression was performed to assess the independent impact of LYZ on glioma prognosis. A nomogram was constructed and validated across multi-center cohorts (including our center, TMA, CGGA datasets). Correlations between LYZ and immune checkpoints/immune cell infiltration were evaluated, with GO/KEGG enrichment analysis to reveal underlying regulatory pathways. Results LYZ was significantly overexpressed in 23 cancer types (including glioma). In glioma, high LYZ expression inversely correlated with stemness but showed complex associations with genomic instability. TCGA data revealed that elevated LYZ was strongly associated with worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI), with hazard ratios (HR) of 3.94, 4.02, and 2.31, respectively, and all P values < 0.001.Multivariate models confirmed its independence from WHO grade (HR = 1.471, P = 0.037), validated consistently across multi-center cohorts (P < 0.001). LYZ positively correlated with immune infiltrates (e.g., macrophages) and modulated antigen presentation and innate immune pathways. Conclusion LYZ is aberrantly overexpressed in glioma, serving as an independent prognostic biomarker. It may promote tumorigenesis by reshaping the immune microenvironment, offering potential synergy with immune checkpoint blockade as a therapeutic target.
Related
- Expression, prognostic association, and immune microenvironment correlates of C4orf50 in breast cancer: a The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) bioinformatics study
- Prognostic significance of CCT5 in breast cancer and its regulatory mechanisms in promoting tumorigenesis
- Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects
- Molecular mechanisms regulating differential expression of individual miRNAs within polycistronic clusters.
- Single-cell and spatial multi-omics combined with machine learning to unravel the heterogeneity of cholangiocarcinoma and the WFDC3-mediated prognostic regulatory mechanisms
BibTeX
@article{zhang2026differential,
title = {{Differential expression of LYZ across pan-cancer and its prognostic value and immune microenvironment regulatory mechanisms in glioma}},
author = {Mengting Zhang and Jiayuan Li and Zheng Liu and Zihan Chen and Zhiqing Xiao and Yanqiang Wang and Lei Tian and Yaling Yue and Liubing Hou and Huandi Zhou and Xiaoying Xue},
journal = {Discover Oncology},
year = {2026},
month = jul,
doi = {10.1007/s12672-026-05618-5},
url = {https://doi.org/10.1007/s12672-026-05618-5},
note = {CC BY},
}
RIS
TY - JOUR
TI - Differential expression of LYZ across pan-cancer and its prognostic value and immune microenvironment regulatory mechanisms in glioma
AU - Mengting Zhang
AU - Jiayuan Li
AU - Zheng Liu
AU - Zihan Chen
AU - Zhiqing Xiao
AU - Yanqiang Wang
AU - Lei Tian
AU - Yaling Yue
AU - Liubing Hou
AU - Huandi Zhou
AU - Xiaoying Xue
PY - 2026
DA - 2026/07/01
JO - Discover Oncology
DO - 10.1007/s12672-026-05618-5
UR - https://doi.org/10.1007/s12672-026-05618-5
AB - Purpose To investigate the expression patterns of the immune factor Lysozyme (LYZ) across pan-cancer, with a focus on elucidating its prognostic value, molecular mechanisms, and association with the immune microenvironment in glioma, aiming to identify novel therapeutic targets for precision oncology. Methods Utilizing The Cancer Genome Atlas (TCGA) pan-cancer datasets, we analyzed differential expression of LYZ between tumor and normal tissues, correlated clinical features, tumor stemness, and prognosis. Univariate/multivariate Cox regression was performed to assess the independent impact of LYZ on glioma prognosis. A nomogram was constructed and validated across multi-center cohorts (including our center, TMA, CGGA datasets). Correlations between LYZ and immune checkpoints/immune cell infiltration were evaluated, with GO/KEGG enrichment analysis to reveal underlying regulatory pathways. Results LYZ was significantly overexpressed in 23 cancer types (including glioma). In glioma, high LYZ expression inversely correlated with stemness but showed complex associations with genomic instability. TCGA data revealed that elevated LYZ was strongly associated with worse overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI), with hazard ratios (HR) of 3.94, 4.02, and 2.31, respectively, and all P values < 0.001.Multivariate models confirmed its independence from WHO grade (HR = 1.471, P = 0.037), validated consistently across multi-center cohorts (P < 0.001). LYZ positively correlated with immune infiltrates (e.g., macrophages) and modulated antigen presentation and innate immune pathways. Conclusion LYZ is aberrantly overexpressed in glioma, serving as an independent prognostic biomarker. It may promote tumorigenesis by reshaping the immune microenvironment, offering potential synergy with immune checkpoint blockade as a therapeutic target.
SN - 2730-6011
ER -